Clinical Trial Update: Parathyroid Hormone (PTH) Attenuation Trial in Hemodialysis-1 [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating a parathyroid hormone attenuation strategy in hemodialysis patients with secondary hyperparathyroidism and end-stage renal disease ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• End-stage Renal Disease
• Hyperparathyroidism

Drugs mentioned

• Parathyroid Hormone Attenuation Agent

Snippet

Sponsor: Pathalys Pharma | Conditions: Secondary Hyperparathyroidism, End-stage Kidney Disease (ESKD) | Phase 3 | Status: COMPLETED